MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 565087 | Name: Teneligliptin
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Teneligliptin is a long-acting, orally-bioavailable inhibitor of dipeptidyl peptidase-4 (DPP-4), with hypoglycemic activity.

Chemical Structure

Teneligliptin
Teneligliptin
CAS#760937-92-6 (free base)

Theoretical Analysis

MedKoo Cat#: 565087

Name: Teneligliptin

CAS#: 760937-92-6 (free base)

Chemical Formula: C22H30N6OS

Exact Mass: 426.2202

Molecular Weight: 426.58

Elemental Analysis: C, 61.94; H, 7.09; N, 19.70; O, 3.75; S, 7.52

Price and Availability

Size Price Availability Quantity
10mg USD 400.00 2 Weeks
50mg USD 800.00 2 Weeks
100mg USD 1,050.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
760937-92-6 (free base) 906093-29-6 (HBr) 1572583-29-9 (HBr hydrate)
Synonym
Teneligliptin
IUPAC/Chemical Name
[(2S,4S)-4-[4-(5-Methyl-2-phenylpyrazol-3-yl)piperazin-1-yl]pyrrolidin-2-yl]-(1,3-thiazolidin-3-yl)methanone
InChi Key
WGRQANOPCQRCME-PMACEKPBSA-N
InChi Code
InChI=1S/C22H30N6OS/c1-17-13-21(28(24-17)18-5-3-2-4-6-18)26-9-7-25(8-10-26)19-14-20(23-15-19)22(29)27-11-12-30-16-27/h2-6,13,19-20,23H,7-12,14-16H2,1H3/t19-,20-/m0/s1
SMILES Code
O=C([C@H]1NC[C@@H](N2CCN(C3=CC(C)=NN3C4=CC=CC=C4)CC2)C1)N5CSCC5
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 426.58 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Wang G, Fu J, Li X, Wang J, Zhai J, Du B. Comparative efficacy and safety of dipeptidyl peptidase-4 inhibitors in adults with type 2 diabetes mellitus: A network meta-analysis. Diabetes Obes Metab. 2024 Dec 6. doi: 10.1111/dom.16114. Epub ahead of print. PMID: 39639837. 2: Manchi RK, Chenchula S, Haritha M. Effectiveness and Safety of Metformin, Teneligliptin, and Glimepiride Combination Therapy in Type 2 Diabetes: A Quasi Experimental Clinical Trial. Curr Diabetes Rev. 2024 Nov 29. doi: 10.2174/0115733998292943240730115310. Epub ahead of print. PMID: 39620331. 3: Lee SO, Kuthati Y, Huang WH, Wong CS. Semaglutide Ameliorates Diabetic Neuropathic Pain by Inhibiting Neuroinflammation in the Spinal Cord. Cells. 2024 Nov 8;13(22):1857. doi: 10.3390/cells13221857. PMID: 39594606; PMCID: PMC11593193. 4: Shimoda M, Katakura Y, Mashiko A, Iwamoto M, Nakanishi S, Anno T, Kawasaki F, Obata A, Fushimi Y, Sanada J, Kohara K, Isobe H, Iwamoto Y, Hirukawa H, Tatsumi F, Kimura Y, Kimura T, Mune T, Kaku K, Kaneto H. Comparison of protective effects of teneligliptin and luseogliflozin on pancreatic β-cell function: randomized, parallel-group, multicenter, open-label study (SECRETE-I study). Front Endocrinol (Lausanne). 2024 Oct 21;15:1412553. doi: 10.3389/fendo.2024.1412553. PMID: 39497800; PMCID: PMC11532122. 5: Guo J, Cao Y, Wu QY, Cen LS. Potential mechanism of teneligliptin in the treatment of diabetic cardiomyopathy. World J Diabetes. 2024 Oct 15;15(10):2002-2005. doi: 10.4239/wjd.v15.i10.2002. PMID: 39493566; PMCID: PMC11525723. 6: Mohammadi S, Al-Harrasi A. Macrophage modulation with dipeptidyl peptidase-4 inhibitors: A new frontier for treating diabetic cardiomyopathy? World J Diabetes. 2024 Sep 15;15(9):1847-1852. doi: 10.4239/wjd.v15.i9.1847. PMID: 39280186; PMCID: PMC11372644. 7: Takada H, Matsumura T, Shimamura H, Matsui M, Kon S, Fukumoto A, Kubota T, Yoshida K, Iwahashi H, Takahashi MP. Investigation of Glucose Metabolism by Continuous Glucose Monitoring and Validation of Dipeptidyl Peptidase 4 Inhibitor Use in Patients with Myotonic Dystrophy Type 1. J Clin Med. 2024 Sep 5;13(17):5252. doi: 10.3390/jcm13175252. PMID: 39274465; PMCID: PMC11396113. 8: Patel R, Kotadiya R. Stability-indicating green HPLC method for fixed-dose tablets containing remogliflozin etabonate and teneligliptin: an AQbD approach. Drug Dev Ind Pharm. 2024 Aug;50(8):750-762. doi: 10.1080/03639045.2024.2400199. Epub 2024 Sep 11. PMID: 39226128. 9: Al Madhoun A. Teneligliptin: A potential therapeutic approach for diabetic cardiomyopathy. World J Diabetes. 2024 Aug 15;15(8):1654-1658. doi: 10.4239/wjd.v15.i8.1654. PMID: 39192857; PMCID: PMC11346098. 10: Fernandez CJ, Shetty S, Pappachan JM. Diabetic cardiomyopathy: Emerging therapeutic options. World J Diabetes. 2024 Aug 15;15(8):1677-1682. doi: 10.4239/wjd.v15.i8.1677. PMID: 39192854; PMCID: PMC11346103. 11: Isogawa M, Makino H, Son C, Nishimura K, Hirata T, Kasama S, Miyamoto Y, Noguchi M, Kasahara M, Hosoda K. Comparison of canagliflozin and teneligliptin on energy intake and body weight in Japanese patients with Type 2 diabetes: a subanalysis of the CANTABILE study. BMC Endocr Disord. 2024 Aug 19;24(1):153. doi: 10.1186/s12902-024-01690-6. PMID: 39160513; PMCID: PMC11331643. 12: Shaik AR, Kohli S, Vohora D. Bone effects of metformin monotherapy and its combination with teneligliptin: A 12-week follow-up study in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2024 Jul;213:111744. doi: 10.1016/j.diabres.2024.111744. Epub 2024 Jun 13. PMID: 38878869. 13: Akabari AH, Gajiwala H, Patel SK, Surati J, Solanki D, Shah KV, Patel TJ, Patel SP. Stability-Indicating TLC-Densitometric and HPLC Methods for Simultaneous Determination of Teneligliptin and Pioglitazone in Pharmaceutical Dosage Forms with Eco-Friendly Assessment. J Chromatogr Sci. 2024 Jun 5:bmae038. doi: 10.1093/chromsci/bmae038. Epub ahead of print. PMID: 38836346. 14: Gnanasegaran S, Gopal S, Adhimoolam M, Raj GM, Velayudhan S, Yuvaraj M. Evaluation of microalbuminuria in type-2 diabetes mellitus under oral hypoglycemic agents: Association with age, sex, BMI, and renal clearance. J Family Med Prim Care. 2024 Mar;13(3):938-943. doi: 10.4103/jfmpc.jfmpc_1286_23. Epub 2024 Apr 4. PMID: 38736791; PMCID: PMC11086784. 15: Zhang GL, Liu Y, Liu YF, Huang XT, Tao Y, Chen ZH, Lai HL. Teneligliptin mitigates diabetic cardiomyopathy by inhibiting activation of the NLRP3 inflammasome. World J Diabetes. 2024 Apr 15;15(4):724-734. doi: 10.4239/wjd.v15.i4.724. PMID: 38680706; PMCID: PMC11045420. 16: Senzaki T, Saito Y, Kobayashi S. Reductive N-Alkylation of Amines with Ketones Using Heterogeneous Polysilane-Palladium Catalysts under Continuous-Flow Conditions. Org Lett. 2024 May 10;26(18):3772-3777. doi: 10.1021/acs.orglett.4c00876. Epub 2024 Apr 26. PMID: 38666753. 17: Menda J, Chintala V, Kanuparthy PR, Katari NK, Kowtharapu LP, Jonnalagadda SB. Quality by Design Tool Assessed Ultraperformance Liquid Chromatography Method for the Analysis of Remogliflozin and Teneligliptin in Oral Dosage Form. ACS Omega. 2024 Mar 7;9(11):12553-12563. doi: 10.1021/acsomega.3c04589. PMID: 38524417; PMCID: PMC10955570. 18: Iijima H, Shimizu H, Mori-Anai K, Kawaguchi A, Mochida Y, Yamauchi T, Kadowaki T. Publisher Correction: Evaluation of Age-Related Changes in Teneligliptin Pharmacokinetics in Japanese and European Descent Subjects Using a Physiologically Based Pharmacokinetic Model. Diabetes Ther. 2024 Apr;15(4):779-780. doi: 10.1007/s13300-024-01548-z. Erratum for: Diabetes Ther. 2024 Apr;15(4):763-777. doi: 10.1007/s13300-023-01514-1. PMID: 38421560; PMCID: PMC10951140. 19: Zhu M, Guan R, Ma G. Efficacy and safety of teneligliptin in patients with type 2 diabetes mellitus: a Bayesian network meta-analysis. Front Endocrinol (Lausanne). 2023 Dec 18;14:1282584. doi: 10.3389/fendo.2023.1282584. PMID: 38189048; PMCID: PMC10766708. 20: Pelluri R, Kongara S, Nagasubramanian VR, Mahadevan S, Chimakurthy J. Effect of Teneligliptin 20 mg Twice Daily on Glucagon-Like Peptide-1 Levels and Its Influence on Non-Glycemic Components in Non-Diabetic Obese Individuals. Metab Syndr Relat Disord. 2024 Mar;22(2):90-96. doi: 10.1089/met.2023.0218. Epub 2024 Jan 3. PMID: 38165660.